Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

American consumer health company Kenvue's Board of Directors announced new actions to unlock shareholder value and an interim ...

Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, ...

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the ...

Echoing this, short-term traders are also sporting a call-bias. This is per the security's Schaeffer's put/call open interest ...

Kenvue stock approaches a Golden Cross, signaling bullish momentum with the stock up 10% over the past month. Legal win over Tylenol gelcaps boosts Kenvue's momentum, as strong brand power fuels ...

It’s a decisive week for investors looking to get involved in Johnson & Johnson’s record split-off of most of its $40 billion stake in Kenvue Inc., the maker of Tylenol and Listerine.

Why It Matters: Kenvue’s stock price has remained relatively unchanged this year, in contrast to the S&P 500 index’s 23% increase.The company’s biggest competitors include Haleon, the parent ...

Shares of Kenvue Inc. KVUE gained nearly 5% Tuesday morning after a federal court’s ruling in a product-liability case appeared to work in the Tylenol maker’s favor. The case involves multiple ...

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the ...